Vaxart, Inc. Deferred Revenue (Non-Current)
Vaxart, Inc. (VXRT) had Deferred Revenue (Non-Current) of $1.52 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2026-08-06
- 2026-06-30: Deferred Revenue, Noncurrent $1.52M.
- 2025-12-31: Deferred Revenue, Noncurrent $2.02M.
- 2018-12-31: Deferred Revenue, Noncurrent $14.41M.
- 2018-09-30: Deferred Revenue, Noncurrent $14.30M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2026-06-30 | $1.52M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $2.02M 10-Q · filed 2026-08-06 |
| 2018-12-31 | $14.41M 10-K · filed 2019-02-06 |
| 2018-09-30 | $14.30M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $13.92M 10-Q · filed 2018-08-10 |
| 2018-03-31 | $14.56M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $16.00M 10-Q · filed 2018-02-06 |
| 2017-09-30 | $15.40M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $15.30M 10-Q · filed 2018-02-06 |
| 2017-03-31 | $16.70M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $17.60M 10-Q · filed 2017-02-06 |
| 2016-09-30 | $17.20M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $16.80M 10-K · filed 2017-09-01 |
| 2012-09-30 | $30.95M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $31.58M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $32.21M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $32.84M 10-Q · filed 2012-11-08 |
| 2011-09-24 | $33.47M 10-Q · filed 2011-11-02 |
| 2011-06-25 | $34.11M 10-Q · filed 2011-08-03 |
| 2010-12-25 | $35.37M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |